ArticleVirology journal2016
Seroprevalence of Orthopoxvirus in rural Brazil: insights into anti-OPV immunity status and its implications for emergent zoonotic OPV.
Article in Virology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- Vaccinia and Monkeypox Virus-Neutralizing Antibodies in People Living with HIV: A Serological Study in a Orthopoxvirus-Endemic, Low-Income Region in Brazil.Pathogens (Basel, Switzerland) · 2025Article
- The Peculiar Emergence of Mpox (Monkeypox): Directions for the Search for the Natural Reservoir and Vaccination Strategies.Vaccines · 2024Article
- Phylogeny-aware linear B-cell epitope predictor detects targets associated with immune response to orthopoxviruses.Briefings in bioinformatics · 2024Article
- Differential diagnosis of exanthematous viruses during the 2022 Mpox outbreak in Minas Gerais, Brazil.Journal of clinical microbiology · 2024Article
- The global landscape of smallpox vaccination history and implications for current and future orthopoxvirus susceptibility: a modelling study.The Lancet. Infectious diseases · 2023Article
- Article
- Comparative Pathology of Zoonotic Orthopoxviruses.Pathogens (Basel, Switzerland) · 2022Review
- Monkeypox 2022 outbreak in non-endemic countries: Open questions relevant for public health, nonpharmacological intervention and literature review.Frontiers in cellular and infection microbiology · 2022Review
- Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus.Frontiers in immunology · 2022Article
- Educational Approach to Prevent the Burden of Vaccinia Virus Infections in a Bovine Vaccinia Endemic Area in Brazil.Pathogens (Basel, Switzerland) · 2021Article
- Twenty Years after Bovine Vaccinia in Brazil: Where We Are and Where Are We Going?Pathogens (Basel, Switzerland) · 2021Review
- Silent Circulation of the Saint Louis Encephalitis Virus among Humans and Equids, Southeast Brazil.Viruses · 2019Article
- Silent Orthohantavirus Circulation Among Humans and Small Mammals from Central Minas Gerais, Brazil.EcoHealth · 2018Article
- Bovine Vaccinia: Insights into the Disease in Cattle.Viruses · 2018Review
- Review
- Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?Viruses · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBovine vaccinia (BV) is a zoonosis caused by Vaccinia virus, a virus from Orthopoxvirus genus (OPV) that affects mainly cattle herds and humans in rural areas in Brazil. Because most studies have focused on outbreaks situations, data on BV epidemiology is limited. A cross sectional study in Brazilian rural areas during 2012-2013 was conducted to determine the neutralizing antibodies seroprevalence and risk factors for BV.
methodsA structured questionnaire was applied to elicit demographics data and farming practices considered risk factors for BV exposure. Neutralizing anti-OPV antibodies were investigated using plaque reduction neutralization test. The neutralizing antibodies prevalence rates were calculated and the risk factor analysis was performed using multivariate logistic regression.
resultsTwo hundred and forty participants were enrolled in this study with a prevalence of neutralizing antibodies of 30.8 % (95 % confidence interval [CI], 25.3-36.9). In multivariate analysis, age > 35 years (Odds Ratio [OR] = 18.2; CI 95 % = 7.7 - 43.2) and previous outbreak in property (OR = 3.9; C I95 % = 1.2 - 12.6) were independently associated with anti-OPV neutralizing antibodies.
conclusionsIn this study, anti-OPV protective immunity (neutralizing antibody titers) was assessed in an endemic BV Brazilian rural area. Our findings indicate that epidemiological surveillance is required and should be applied by public health authorities to create interventions and/or prevention strategies to avoid viral spread causing future outbreaks among individuals who are under risk of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.